Santoni M.; Massari F.; Bracarda S.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Basso U.; Aurilio G.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Mollica V.; Rizzo A.; Battelli N., Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors, «EUROPEAN UROLOGY FOCUS», 2022, 22, pp. 49 - 55 [articolo]
Rizzo A.; Mollica V.; Santoni M.; Massari F., Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 6356, pp. 1 - 3 [articolo]Open Access
Medici, Federica; Siepe, Giambattista; Strigari, Lidia; Massari, Francesco; Buwenge, Milly; Bisello, Silvia; Castellucci, Paolo; Fanti, Stefano; Cammelli, Silvia; Morganti, Alessio Giuseppe, CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report, «MOLECULAR AND CLINICAL ONCOLOGY», 2022, 16, Article number: 85, pp. 1 - 5 [articolo]Open Access
Rizzo A.; Mollica V.; Santoni M.; Massari F., Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 482 - 487 [articolo]
Viscardi G.; Tralongo A.C.; Massari F.; Lambertini M.; Mollica V.; Rizzo A.; Comito F.; Di Liello R.; Alfieri S.; Imbimbo M.; Della Corte C.M.; Morgillo F.; Simeon V.; Lo Russo G.; Proto C.; Prelaj A.; De Toma A.; Galli G.; Signorelli D.; Ciardiello F.; Remon J.; Chaput N.; Besse B.; de Braud F.; Garassino M.C.; Torri V.; Cinquini M.; Ferrara R., Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis, «EUROPEAN JOURNAL OF CANCER», 2022, 177, pp. 175 - 185 [articolo]
Mollica V.; Santoni M.; Matrana M.R.; Basso U.; De Giorgi U.; Rizzo A.; Maruzzo M.; Marchetti A.; Rosellini M.; Bleve S.; Maslov D.; Tawagi K.; Philon E.; Blake Z.; Massari F., Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma, «TARGETED ONCOLOGY», 2022, 17, pp. 61 - 68 [articolo]
Santoni M.; Molina-Cerrillo J.; Myint Z.W.; Massari F.; Buchler T.; Buti S.; Matrana M.R.; De Giorgi U.; Rizzo M.; Zabalza I.O.; Galli L.; Zucali P.A.; Aurilio G.; Incorvaia L.; Bassanelli M.; Mammone G.; Salfi A.; Isella L.; Mollica V.; Grande E.; Porta C.; Battelli N., Concomitant Use of Statins, Metformin, or Proton Pump Inhibitors in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Combination Therapies, «TARGETED ONCOLOGY», 2022, 17, pp. 571 - 581 [articolo]
Ciccarese C.; Iacovelli R.; Buti S.; Primi F.; Astore S.; Massari F.; Ferrara M.G.; Palermo G.; Foschi N.; Iacovelli V.; Rossi E.; Schinzari G.; Bove P.; Bassi P.; Bria E.; Tortora G., Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?, «ANTICANCER RESEARCH», 2022, 42, pp. 1487 - 1493 [articolo]
Di Sciascio L.; Ambrosi F.; Franceschini T.; Giunchi F.; Franchini E.; Massari F.; Bianchi F.M.; Colecchia M.; Fiorentino M.; Ricci C., Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?, «PATHOLOGY RESEARCH AND PRACTICE», 2022, 234, Article number: 153937, pp. 153937 - 153937 [articolo]
Nigro M.C.; Mollica V.; Marchetti A.; Cheng M.; Rosellini M.; Montironi R.; Cheng L.; Massari F., Current androgen receptor antagonists under investigation for resistant prostate cancer, «EXPERT REVIEW OF ANTICANCER THERAPY», 2022, 22, pp. 191 - 202 [articolo]
Molina-Cerrillo J.; Santoni M.; Ruiz A.; Massari F.; Pozas J.; Ortego I.; Gomez V.; Grande E.; Alonso-Gordoa T., Epigenetics in advanced renal cell carcinoma: Potential new targets, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2022, 180, Article number: 103857, pp. 103857 - 103866 [articolo]
Rizzo A.; Mollica V.; Massari F., Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis, «EUROPEAN UROLOGY FOCUS», 2022, 8, pp. 152 - 159 [articolo]
Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J., Genomics and Immunomics in the Treatment of Urothelial Carcinoma, «CURRENT ONCOLOGY», 2022, 29, pp. 3499 - 3518 [articolo]Open Access
Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F., Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2022, 7, pp. 131 - 149 [articolo]
Rebuzzi S.E.; Rescigno P.; Catalano F.; Mollica V.; Vogl U.M.; Marandino L.; Massari F.; Mestre R.P.; Zanardi E.; Signori A.; Buti S.; Bauckneht M.; Gillessen S.; Banna G.L.; Fornarini G., Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives, «CANCERS», 2022, 14, Article number: 1245, pp. 1 - 16 [articolo]Open Access
